Zabihollah Shoja1, Mohammad Farahmand2, Neda Hosseini2, Somayeh Jalilvand3. 1. Department of Virology, Pasteur Institute of Iran, Tehran, Iran. 2. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 3. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran, sjalilvand@tums.ac.ir.
Abstract
INTRODUCTION: To date, the human papillomavirus (HPV) vaccine has not been integrated into the national vaccination program of most countries of the WHO Eastern Mediterranean Region (EMRO), except for the United Arab Emirates and Libya. The knowledge of HPV genotype distribution in cervical neoplasia is valuable to predict the impact of current HPV vaccines on cancer prevention and can help the health policymakers to select the most appropriate vaccine types in their countries. METHODS: Hence, this meta-analysis recapitulates all available data on HPV prevalence and genotypes in women with atypical squamous cells of undetermined significance (ASCUS), cervical intraepithelial neoplasia (CIN) I-III or low- and high-grade squamous intraepithelial lesions (LSIL and HSIL, respectively), and invasive cervical cancer (ICC) in EMRO countries. RESULTS: The meta-analysis included 5,990 cases of cervical precancer and cancer. The overall HPV prevalence was 85.4, 71.3, 59.2, and 34.8% in women with ICC, CIN II-III or HSIL, CIN I or LSIL, and ASCUS, respectively. HPV 16 was the most common genotype followed by HPV 18, representing 58 and 16.5% in ICC cases, respectively. CONCLUSION: This meta-analysis showed that the introduction of current HPV vaccines into national vaccination programs and the establishment of comprehensive screening programs in EMRO countries is beneficial by preventing 74.5% of cervical neoplasia.
INTRODUCTION: To date, the human papillomavirus (HPV) vaccine has not been integrated into the national vaccination program of most countries of the WHO Eastern Mediterranean Region (EMRO), except for the United Arab Emirates and Libya. The knowledge of HPV genotype distribution in cervical neoplasia is valuable to predict the impact of current HPV vaccines on cancer prevention and can help the health policymakers to select the most appropriate vaccine types in their countries. METHODS: Hence, this meta-analysis recapitulates all available data on HPV prevalence and genotypes in women with atypical squamous cells of undetermined significance (ASCUS), cervical intraepithelial neoplasia (CIN) I-III or low- and high-grade squamous intraepithelial lesions (LSIL and HSIL, respectively), and invasive cervical cancer (ICC) in EMRO countries. RESULTS: The meta-analysis included 5,990 cases of cervical precancer and cancer. The overall HPV prevalence was 85.4, 71.3, 59.2, and 34.8% in women with ICC, CIN II-III or HSIL, CIN I or LSIL, and ASCUS, respectively. HPV 16 was the most common genotype followed by HPV 18, representing 58 and 16.5% in ICC cases, respectively. CONCLUSION: This meta-analysis showed that the introduction of current HPV vaccines into national vaccination programs and the establishment of comprehensive screening programs in EMRO countries is beneficial by preventing 74.5% of cervical neoplasia.
Authors: Eduardo Gil Perez-Bacho; Fredy Omar Beltrán-Anaya; Elena Arechaga-Ocampo; Daniel Hernández-Sotelo; Olga Lilia Garibay-Cerdenares; Berenice Illades-Aguiar; Luz Del Carmen Alarcón-Romero; Oscar Del Moral-Hernández Journal: Viruses Date: 2022-05-05 Impact factor: 5.818
Authors: John Charles Rotondo; Lucia Oton-Gonzalez; Chiara Mazziotta; Carmen Lanzillotti; Maria Rosa Iaquinta; Mauro Tognon; Fernanda Martini Journal: Front Microbiol Date: 2020-11-19 Impact factor: 5.640
Authors: Narcisa Muresu; Giovanni Sotgiu; Silvia Marras; Davide Gentili; Illari Sechi; Andrea Cossu; Arianna Dettori; Roberto Enrico Pietri; Luisa Paoni; Maria Eugenia Ghi; Maria Paola Bagella; Adriano Marrazzu; Antonio Cossu; Antonio Genovesi; Andrea Piana; Laura Saderi Journal: Int J Environ Res Public Health Date: 2022-01-08 Impact factor: 3.390